Contraindicated (1)bortezomib will improve the stage or outcome of mavacamten by influencing hepatic enzyme CYP2C19 metabolism. Contraindicated. Strong or moderate CYP2C19 inhibitors might enhance mavacamten systemic publicity, leading to heart failure resulting from systolic dysfunction. chloramphenicol will raise the level or influence of bortezomib by influencing hepatic/intestinal... https://cf5380246.rimmablog.com/26514811/the-ultimate-guide-to-crenolanib